1. Home
  2. NVAX

as of 12-02-2025 3:47pm EST

$6.65
+$0.04
+0.68%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Chart Type:
Time Range:
Founded: 1987 Country:
United States
United States
Employees: N/A City: GAITHERSBURG
Market Cap: 1.1B IPO Year: 1995
Target Price: $10.78 AVG Volume (30 days): 4.2M
Analyst Decision: Hold Number of Analysts: 9
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: 2.07 EPS Growth: N/A
52 Week Low/High: $5.01 - $11.55 Next Earning Date: 11-06-2025
Revenue: $1,064,651,000 Revenue Growth: 20.27%
Revenue Growth (this year): 58.91% Revenue Growth (next year): -66.51%

AI-Powered NVAX Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 2 days ago

AI Recommendation

hold
Model Accuracy: 72.90%
72.90%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: